ProMIS Neurosciences
Develops EpiSelect-discovered antibodies for protein-misfolding neurodegenerative disorders.
Something off on this page? Send us feedback.
Profile
Develops EpiSelect-discovered antibody candidates for Alzheimer's and other neurodegenerative disorders driven by misfolded proteins. With no approved products or revenue, it is a single-segment R&D business whose only clinical-stage candidate is PMN310.
Develops antibodies against disease-specific epitopes exposed on toxic, misfolded proteins through EpiSelect, its computational discovery platform. PMN310, the only clinical-stage candidate, is designed for Alzheimer's disease to bind toxic amyloid-beta oligomers while avoiding monomer, plaque, and vascular deposits.
Advances PMN267 for TDP-43 disorders and PMN442 for alpha-synuclein disorders in preclinical development, alongside the PMN311 and PMN440 vaccine programs. Toronto serves as the registered head office, with an office in Cambridge, Massachusetts, U.S. clinical sites, and Canadian research relationships.
Operates as a small R&D organization with no approved products or product revenue. Manufacturing is intended to be outsourced where practical, and future commercialization is expected to rely on partners; progress is concentrated on PMN310's clinical and regulatory development.
Company facts
Key statistics
Year to date +94.4% · Average volume (30d) 118.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 21, 2026 | Roth Capital | Target | $19 | $29 | |
| Jul 28, 2026 | Chardan Capital | Reiterate | Buy | $20 | $33 |
| Jul 27, 2026 | Chardan Capital | Target | $20 | ||
| Jul 7, 2026 | Roth Capital | Initiate | Buy | $19 | |
| Jun 30, 2026 | Cantor Fitzgerald | Initiate | Overweight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$1.38 | −$1.28 | +7.2% | — | — | — | +0.47% |
| May 12, 2026Q1 FY26 | −$1.06 | −$1.26 | −18.9% | — | — | — | +0.76% |
| May 11, 2026Q1 FY26 | −$1.06 | −$1.26 | −18.9% | — | — | — | −1.78% |
| Mar 25, 2026Q4 FY25 | −$4.66 | −$4.11 | +11.8% | — | — | — | −4.54% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | −$9.4M | $0 | $0 | |
| Operating income | −$7.5M | −$10.2M | −$11.8M | −$10.8M | −$8.6M | −$12.3M | |
| Net income | −$7.3M | −$10.1M | −$11.6M | −$10.7M | −$8.2M | −$11.7M | |
| Diluted EPS | −$5.25 | −$7.25 | −$8.27 | −$6.81 | −$1.26 | −$1.28 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $4.1K · FY22 $0 · FY23 $6.3K · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $53.5M · Total debt $0 · Total assets $56.7M · Shareholders' equity $49.4M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 1.31M · Float 838.2K · 64.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 1.29M | 14.40% | 13G | Apr 7, 2026 |
| Great Point Partners, LLC | 954.1K | 9.99% | 13G | May 15, 2026 |
| ABG V-SIV IX Ltd · 10 percent owner | 943.1K | 72.13% | Form 4 | Feb 25, 2026 |
| ABG Management Ltd. · 10 percent owner | 943.1K | 72.13% | Form 4 | Feb 5, 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 895.9K | 9.99% | 13G | Mar 18, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 5, 2026 | Johanne Kaplan | officer: Chief Development Officer | +2,280 | $13.30 |
| Apr 22, 2026 | Patrick D. Kirwin | director | +4,000 | $11.33 |
| Mar 5, 2026 | Eugene Williams | director | +2,000 | $24.40 |
| Mar 2, 2026 | Eugene Williams | director | +1,000 | $22.53 |
| Mar 3, 2026 | Eugene Williams | director | +1,000 | $21.89 |
Peers
- Eli Lilly
Approved anti-amyloid leader in early Alzheimer's disease.
- Biogen
Leqembi co-developer with an approved early-AD antibody.
- Acumen Pharmaceuticals
Closest clinical rival in soluble amyloid-beta oligomer antibodies.
- AC Immune
Active anti-amyloid vaccine program for early Alzheimer's disease.
- Cognition Therapeutics
Oligomer-toxicity program pursuing the same Alzheimer's patients.
- Annovis Bio
Dual Alzheimer's and Parkinson's program with protein-target breadth.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ProMIS Neurosciences | $13.79 | −0.68% | $18.0M | — | — | — | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Acumen Pharmaceuticals | $2.92 | +0.17% | $210.9M | — | — | — | — |
| AC Immune | $2.65 | −0.56% | $269.7M | — | — | 12.5 | +498.6% |
| Cognition Therapeutics | $1.04 | +1.99% | $91.3M | — | — | — | — |
| Annovis Bio | $1.74 | +1.16% | $73.2M | — | — | — | — |
| Median | 39.0 | 22.6 | 12.5 | +47.7% |